与普通人群相比，智力残疾人群对醋酸艾司利卡西平的反应。

Eslicarbazepine acetate response in intellectual disability population versus general population.

作者信息

Allard Jon, Lawthom Charlotte, Henley William, Mclean Brendan, Hudson Sharon, Tittensor Phil, Rajakulendran Sanjeev, Ellawela Shan, Pace Adrian, Shankar Rohit

机构信息

Cornwall Intellectual Disability & Epilepsy Research (CIDER) Centre Cornwall Partnership NHS Foundation Trust, Bodmin, UK.

Swansea University, Swansea, UK.

出版信息

Acta Neurol Scand. 2021 Mar;143(3):256-260. doi: 10.1111/ane.13368. Epub 2020 Nov 24.

DOI:10.1111/ane.13368

PMID:33131083

Abstract

BACKGROUND

A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited.

AIMS OF STUDY

This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID.

METHODS

A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used.

RESULTS

Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant.

CONCLUSIONS

Tolerance and Efficacy for ID and 'no ID' people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.

摘要